Microbial expression-based fusion protein model
Fusion proteins are increasingly used as functional therapeutic proteins, targeting ligands, cytokine-fusion constructs, immune modulators, and process-enabling materials for advanced therapy development. CATUG’s fusion protein support is built on plasmid construction, microbial fermentation, protein expression, purification, and analytical development capabilities, enabling flexible production of selected recombinant protein formats for research, process development, and CMC-enabling applications.
CATUG positioning
Rather than positioning itself as a full-spectrum mammalian biologics CDMO, CATUG focuses on fusion protein projects that fit microbial expression and stage-appropriate development workflows. Typical applications may include functional proteins, engineered binding proteins, cytokine-related constructs, ligand-fusion proteins, albumin-binding formats, Fc-related exploratory constructs where applicable, and protein materials used to support nucleic acid therapeutics, targeted delivery, or cell therapy development.
Key CMC considerations
Key CMC considerations include construct design, plasmid preparation, host-system selection, expression yield, solubility, aggregation control, purification strategy, endotoxin control, residual host-cell impurity control, identity and purity testing, and documentation readiness.
CATUG integrated support
CATUG can support clients from early feasibility and expression screening to small-scale production, process optimization, analytical characterization, and stage-appropriate material supply. These capabilities are especially relevant for protein materials used as targeting ligands, functional reagents, process-enabling components, or advanced-therapy CMC inputs.
Why CATUG for fusion proteins
CATUG provides flexible and practical protein-production support that complements its core plasmid, RNA, LNP/tLNP, and advanced therapy CMC platforms, helping clients access critical protein materials without forcing projects into oversized biologics manufacturing packages too early.
Nanobody and compact binding protein model
Nanobodies and other compact binding proteins are becoming important enabling materials for targeted delivery, immune-cell targeting, in vivo CAR, tLNP development, and next-generation cell and gene therapy applications. Their small size, modular structure, and potential microbial expression compatibility make them attractive for ligand engineering, targeted LNP conjugation, and exploratory therapeutic or delivery-system development.
Targeting ligand applications
For in vivo CAR and targeted delivery programs, nanobodies can serve as targeting ligands to help direct nucleic acid payloads toward selected immune-cell or tissue targets. In tLNP workflows, nanobody or antibody-fragment ligands may be evaluated for post-insertion, surface conjugation, ligand-lipid conjugate design, or other targeted-delivery strategies, depending on target biology, ligand format, and formulation requirements.
CATUG integrated support
CATUG supports nanobody-related projects through plasmid construction, microbial expression, fermentation process development, purification, analytical characterization, and conjugation-feasibility support where applicable. These capabilities can be integrated with CATUG’s RNA, LNP/tLNP, lipid, and analytical platforms to support targeted delivery feasibility studies and CMC development for advanced therapeutic programs.
Key development considerations
Key development considerations include expression yield, solubility, binding activity, purity, endotoxin control, aggregation, residual impurities, ligand compatibility with LNP/tLNP formulation, and analytical methods for identity, purity, and functional characterization.
Why CATUG for nanobody-enabled delivery
CATUG provides flexible nanobody and ligand material support for early feasibility, process development, and targeted delivery CMC exploration, especially where compact binding proteins need to connect with RNA, LNP/tLNP, and advanced therapy workflows.
Biologically produced peptide and peptide-fusion model
Peptides can serve as therapeutic molecules, targeting ligands, linker components, functional motifs, and process-enabling materials across advanced therapy workflows. While many peptides are chemically synthesized, selected peptide or peptide-like products may also be produced through biological expression routes when sequence complexity, fusion format, or conjugation strategy makes recombinant production relevant.
CATUG positioning
CATUG’s peptide-related support is built around plasmid-based microbial expression and biologically produced peptide or peptide-fusion workflows where applicable. This approach may support selected peptide ligands, peptide-fusion proteins, functional motifs, and engineered peptide materials used in targeted delivery, RNA-LNP/tLNP development, cell therapy support, or exploratory therapeutic programs.
Key CMC considerations
For peptide and peptide-fusion projects, key CMC considerations include sequence design, expression strategy, solubility, proteolytic stability, purification, identity and purity testing, endotoxin control, aggregation risk, conjugation compatibility, and documentation.
CATUG integrated support
CATUG can support early feasibility, small-scale production, analytical characterization, and stage-appropriate material supply for projects that fit biological production routes. These capabilities may be especially relevant where peptides are used as targeting ligands, linker-associated components, functional domains, or process-enabling materials.
Why CATUG for peptide-enabled workflows
CATUG’s peptide support complements its broader nucleic acid and delivery-system platforms, particularly where peptides act as targeting ligands, functional domains, or biologically produced components in advanced therapeutic development.
CATUG supports selected microbial expression-based fusion proteins, peptide / peptide-fusion materials, nanobodies, and targeting ligand inputs for advanced therapeutics, including RNA-LNP / tLNP delivery, in vivo CAR, cell therapy, metabolic disease, and CMC-enabling applications.
CATUG does not position itself as a full-spectrum mammalian biologics CDMO. The focus is on microbial expression-compatible proteins, peptide-fusion materials, nanobodies, and targeting ligands that complement CATUG's plasmid, RNA, LNP / tLNP, and advanced therapy CMC platforms.
Supports selected recombinant fusion proteins, cytokine-related constructs, ligand-fusion proteins, albumin-binding formats, Fc-related exploratory constructs where applicable, and functional protein materials for CMC-enabling applications.
Supports selected biologically produced peptides, peptide-fusion formats, GLP-1-like peptide backbones, functional peptide motifs, and linker / fusion strategies where microbial expression routes are technically and economically relevant.
Nanobodies and compact binding proteins can serve as targeting heads for immune-cell targeting, in vivo CAR delivery, tLNP development, targeted RNA delivery, and next-generation cell and gene therapy applications.
CATUG's value is not limited to targeting heads. The same microbial expression and purification foundation can support selected fusion proteins, peptide backbones, nanobody ligands, and process-enabling materials across different advanced therapy workflows.
Selected peptide or peptide-fusion formats, including GLP-1-like backbones where biological expression is suitable.
Ligand-fusion, cytokine-fusion, albumin-binding, and functional protein materials for research and CMC-enabling use.
Nanobody and compact binding proteins for in vivo CAR, tLNP, immune-cell targeting, and targeted RNA delivery.
Focus on yield, solubility, purity, endotoxin, aggregation, binding activity, identity, and documentation readiness.
CATUG connects plasmid construction, microbial expression, fermentation process development, purification, analytical characterization, nanobody / peptide / fusion protein material supply, and targeted-delivery or therapeutic application feasibility support.
Supports plasmid construction, sequence optimization input, expression construct preparation, backbone selection, and stage-appropriate documentation for fusion protein, nanobody, and peptide-fusion workflows.